A menopause program may combine clinician visits, prescriptions, coaching and an app. Stella’s US service does that, with progesterone among the medicines its clinicians may consider. The breadth can make a program feel complete before the details of an oral capsule have been established. It is worth identifying which part of the service answers which question.
This September 29, 2026 assessment concerns the US Stella clinic and its public FAQ, not a UK care arrangement. It does not confirm a supplied capsule, individual coverage or suitability. No appointment, coaching session, app account or prescription was tested.
In this article
The service names progesterone without identifying a universal capsule
Stella’s US information includes progesterone in its hormone-care descriptions and shows capsules within example care arrangements. Its FAQ says clinicians may prescribe hormonal or nonhormonal treatment depending on the person’s history, symptoms and preferences. That establishes relevant care without making the examples a prescription template.
The reviewed records do not identify one manufacturer, strength or excipient list for every progesterone order. The actual oral preparation must be confirmed if one is proposed. Pandia’s review examines more explicit capsule catalog names, but those names should not be borrowed to fill Stella’s missing product details. A service description and a dispensing label answer different questions.
A clear medicine role makes a broader plan easier to understand
The Stella FAQ allows for care with or without medication and describes choices shaped by a clinician’s assessment. A progesterone discussion therefore should begin with its intended purpose, rather than assume that everyone entering the program needs the same hormone combination. A program’s support features do not determine that clinical decision.
The medicine-role guide helps organize questions about why each proposed treatment is included. FDA information explains the relevant relationship between estrogen and the uterine lining, alongside other benefit-risk considerations. Ask the clinician to connect that context to the actual preparation and situation. This review cannot use a sample plan to decide whether a capsule belongs in an individual’s care.
Coach access does not replace a prescription discussion
According to the FAQ, the app becomes available after the first visit and includes wellness coaching, symptom tools and educational material. These features may help someone organize observations, but they do not identify the medicine dispensed by a pharmacy. A capsule’s ingredients, prescribed use and possible adverse effects require the appropriate professional discussion.
Ask how a question about a medicine reaches the prescribing clinician and when a pharmacist should address a dispensing detail. The follow-up guide keeps those responsibilities distinct. Unlimited coaching language should not be interpreted as unlimited medical appointments, immediate clinician responses or an assurance that a support tool can assess an urgent health concern.
The pharmacy record completes the ingredient inquiry
Stella’s FAQ says prescriptions can be sent to the preferred pharmacy and that medication costs depend on the plan and pharmacy. That arrangement leaves the actual product identity important. A clinic’s statement that it uses FDA-approved options does not tell a reader which capsule shell or filler a selected product contains.
The Prometrium label gives one concrete example, listing peanut oil and gelatin and a peanut-allergy restriction. It is not proof that Stella supplies that brand. Our capsule-excipient guide explains how to ask for the relevant manufacturer’s information. The answer should address the actual order and stated ingredient concern without guessing from a hormone name.
A sleep feature can coexist with unwanted drowsiness
Stella’s support description includes sleep resources and coaching as well as possible medicines. These different elements should not be collapsed into a single promise that progesterone improves sleep. A program testimonial also cannot determine how a specific preparation will affect a person’s alertness or daily activities.
MedlinePlus identifies dizziness and drowsiness as possible effects of oral progesterone. The drowsiness guide helps frame practical questions about work, driving and other medicines for the clinician or pharmacist. A useful plan explains where to report a troubling effect. Neither the app nor this review supplies an instruction to change a prescription to address it.
Visit charges do not purchase an identified medicine supply
The US FAQ lists $200 for an initial self-pay visit and $90 for subsequent visits. It reports an average insured copay of $45, with plan variation. The average is not a promise about someone’s bill, and a superbill is a document for possible reimbursement rather than confirmation that an insurer will pay.
Prescription costs are separate and depend on the selected pharmacy benefit. No complete progesterone-capsule price, universal cancellation deadline or refund outcome was established. Wisp’s review examines another service that separates a care charge from local-pharmacy medicine costs. Comparing these amounts requires identifying whether the unit is a visit, ongoing care or the actual dispensed product.
The stated age range is an access boundary, not a safety decision
Stella’s FAQ describes its program for women aged thirty-five to seventy. That public range deserves to remain visible, particularly for an older reader comparing services. Being within it does not establish clinical eligibility for hormones or confirm an appointment format, state arrangement or insurance benefit for a particular person.
The strongest supported conclusion is a US virtual menopause service with several kinds of support and possible progesterone prescribing. The remaining capsule questions are specific: which preparation, which role, which label and which professional handles a concern? Keeping those answers separate makes the broader program easier to assess without claiming clinical superiority or presuming that every person needs medication.
Sources for this article
Source type matters. A provider page describes an offer; an exact product label describes that medicine.
- Stella: US virtual menopause clinicUS provider clinical service and example plans; examples do not establish a universal oral preparation or individual outcome · Checked 2026-09-29
- Stella US: frequently asked questionsDated US provider age range, visit fees, pharmacy and coaching scope; no exact capsule ingredients, guaranteed reimbursement or UK offer inferred · Checked 2026-09-28
- FDA: MenopauseCurrent federal patient guidance; product-dependent benefits/risks and prevention limits, no personal eligibility or class-wide label-change inference · Checked 2026-09-29
- DailyMed: Prometrium progesterone capsulesExact Acertis product labeling updated July23,2026; oral micronized progesterone, peanut oil/gelatin and peanut-allergy restriction, not a label for every provider or generic · Checked 2026-09-29
- MedlinePlus: ProgesteroneFederal medication information; oral-capsule identity, possible dizziness/drowsiness and professional discussion only; public schedules not reproduced as reader instructions · Checked 2026-09-29